MEM INST OSWALDO CRUZ, RIO DE JANEIRO, 111(9) September 2016
PAGES: 592-593 DOI: 10.1590/0074-02760160142 Genome announcement and Highlights
Draft genome sequence of Acinetobacter pittii ST643 shared by cystic fibrosis patients

Géssica A Rocha1, Alex G Ferreira1, Danielle F Lima1, Robson S Leão1, Ana Paula D Carvalho-Assef2, Tânia W Folescu3, Rodolpho M Albano4, Elizabeth A Marques1,+

1Universidade do Estado do Rio de Janeiro, Faculdade de Ciências Médicas, Departamento de Microbiologia, Imunologia e Parasitologia, Rio de Janeiro, RJ, Brasil
2Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Laboratório de Pesquisa em Infecção Hospitalar, Rio de Janeiro, RJ, Brasil
3Fundação Oswaldo Cruz, Instituto Nacional da Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Departamento de Pneumologia Pediátrica, Rio de Janeiro, RJ, Brasil
4Universidade do Estado do Rio de Janeiro, Instituto de Biologia Roberto Alcântara Gomes, Departamento de Bioquímica, Rio de Janeiro, RJ, Brasil

Abstract

Acinetobacter pittii has emerged as an important hospital pathogen that is associated with outbreaks and drug resistance. In cystic fibrosis (CF) patients, the detection of Acinetobacter spp. is rare; however, we isolated the A. pittii sequence type ST643 in several Brazilian CF patients treated in the same centre. The current study describes the draft genome of A. pittii ST643.

Acinetobacter spp. are important nosocomial pathogens with A. baumannii being the most frequently observed species among clinical isolates (Peleg et al. 2008). However, in recent years, an increasing number of studies have highlighted the clinical significance of other Acinetobacter species, especially A. pittii, due to their association with resistance genes and hospital outbreaks (Teixeira et al. 2013, Yamamoto et al. 2013, Pagano et al. 2015). The mechanisms of resistance present in Acinetobacter spp. have been studied extensively, but few investigations have focused on understanding the virulence mechanisms that may contribute to the success of this species (Peleg et al. 2012).

Curiously, Acinetobacter spp. are not common pathogens in cystic fibrosis (CF), from which they are rarely isolated (Coenye et al. 2002). Nevertheless, we were successful in isolating Acinetobacter spp. strains from Brazilian CF patients. The identification of isolates to the species level by polymerase chain reaction (PCR) amplification and sequencing of a segment of the rpoB gene (Gundi et al. 2009) and by multilocus sequence typing (MLST) analysis (Diancourt et al. 2010) demonstrated that five strains (8863, 8876, 8893, 8895, 8941), isolated in the same period from different patients, belonged to sequence type ST643 of A. pittii. The disk diffusion method was performed to determine the antibiotic susceptibility of these isolates using the following antimicrobial agents: amikacin, ampicillin/sulbactam, cefepime, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin/tazobactam and tobramycin (CLSI 2015). Four strains were susceptible to all antimicrobials tested with the exception of cefotaxime. Strain 8876 was multidrug resistant (MDR), which included resistance to ciprofloxacin (quinolones), piperacillin/tazobactam (penicillin-type antibiotic/b-lactamase inhibitor) and cefotaxime (cephalosporins). This A. pittii 8876-ST643 MDR strain was selected for whole-genome sequencing.

This strain was isolated from the sputum of a Brazilian CF patient at Instituto Nacional da Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF-FIOCRUZ), in 2009. A genomic library was constructed by transposon tagmentation with the Nextera XT DNA Sample Prep kit (Illumina Inc., USA). Two sequence runs were performed with the 500- and 300-cycle MiSeq Reagent v. 2 kits on a MiSeq benchtop sequencer (Illumina Inc. USA). A total of 1,445,561 and 1,232,439 paired-end reads for the 500- and 300-cycle kits, respectively, were obtained. Reads were corrected and assembled de novo using the genome assembler Spades 3.5 (Bankevich et al. 2012). The Rapid Annotation using System Technology (RAST) v. 2.0 server (http://rast.nmpdr.org), Center for Genomic Epidemiology website (ResFinder v. 2.1) (https://cge.cbs.dtu.dk//services/ResFinder/), Antibiotic Resistance Genes Database-ARDB (http://ardb.cbcb.umd.edu/) and BLASTP searches against GenBank were used for genome annotation. The resulting 147 scaffolds revealed a genome size of 4,014,293 bp and 74 rRNA genes. Of the 3,785 identified coding sequences, 49% were included in 458 subsystems by RAST, with the main subsystems being amino acids, amino acid derivatives and carbohydrates.

Annotation results indicate the presence of genes associated with virulence, such as those involved in adhesin biosynthesis (pgaA, pgaB, pgaC and pgaD), as well as genes involved in capsular polysaccharide biosynthesis and assembly (wza, wzb and wzc), toxin production (dedA and colicinV) and protein secretion systems (SST IV, SST V and SST VII). Genes associated with resistance to betalactams (blaOXA417 and blaADC-18) and to quinolones (cmeA, cmeB, cmeC and tetR) were also identified. Although mutations in DNA gyrase and topoisomerase IV genes have also been associated with a decreased susceptibility to ciprofloxacin (Chiu et al. 2010), A. pittii 8876-ST643 did not show mutations within the QRDRs of gyrA, gyrB, parC, and parE. In addition to the aforementioned genes associated with the drug-resistance phenotype, genes involved with resistance to bacitracin (bacA), chloramphenicol (ceoB) and macrolides (macA, macB and tolC) were observed.

This genome sequence provides the basis for a future detailed genomic analysis that will certainly increase our understanding of the role of A. pittii in CF patients. This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession LBCP00000000. The version described in this paper is version LBCP01000000.

 

REFERENCES

Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012; 19(5): 455-77.

Chiu CH, Lee HY, Tseng LY, Chen CL, Chia JH, Su LH, et al. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan. Int J Antimicrob Agents. 2010; 35(4): 382-6.

CLSI - Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 25th informational supplement M100-S25. Wayne: NCCLS; 2015.

Coenye T, Goris J, Spilker T, Vandamme P, Lipuma JJ. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of inquilinus limosus gen. nov., sp. nov. J Clin Microbiol. 2002; 40(6): 2062-9.

Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS ONE. 2010; 5(4): e10034.

Gundi VA, Dijkshoorn L, Burignat S, Raoult D, La Scola B. Validation of partial rpoB gene sequence analysis for the identification of clinically important and emerging Acinetobacter species. Microbiology. 2009; 155(Pt7): 2333-41.

Pagano M, Poirel L, Martins AF, Rozales FP, Zavascki AP, Barth AL, et al. Emergence of NDM-1-producing Acinetobacter pittii in Brazil. Int J Antimicrob Agents. 2015; 45(4): 444-5.

Peleg AY, de Breij A, Adams MD, Cerqueira GM, Mocali S, Galardini M, et al. The success of Acinetobacter species; genetic, metabolic and virulence attributes. PLoS ONE. 2012; 7(10): e46984.

Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21(3): 538-82.

Teixeira AB, Martins AF, Barin J, Hermes DM, Pitt CP, Barth AL. First report of carbapenem-resistant Acinetobacter nosocomialis isolates harboring ISAba1-blaOXA-23 genes in Latin America. J Clin Microbiol. 2013; 51(8): 2739-41.

Yamamoto M, Nagao M, Matsumura Y, Hotta G, Matsushima A, Ito Y, et al. Regional dissemination of Acinetobacter species harbouring metallo-β-lactamase genes in Japan. Clin Microbiol Infect. 2013; 19(8): 729-36.

 

Financial support: CNPq, FAPERJ.
+ Corresponding author: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Received 11 April 2016
Accepted 8 July 2016

CONTACT US

Memórias do Instituto Oswaldo Cruz

Av. Brasil 4365, Castelo Mourisco
sala 201, Manguinhos, 21040-900
Rio de Janeiro, RJ, Brazil

Tel.: +55-21-2562-1222

This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

twitterfacebook

SUPPORT PROGRAM

marca fiocruzmarca brasil
marca faperjmarca cnpqmarca capes n marca cope